

# Henry Lik Yuen Chan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6123369/publications.pdf>

Version: 2024-02-01

486  
papers

44,040  
citations

1704

104  
h-index

2828

191  
g-index

488  
all docs

488  
docs citations

488  
times ranked

29520  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study. <i>Journal of Infectious Diseases</i> , 2022, 225, 1967-1973.	4.0	11
2	Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). <i>Gastroenterology</i> , 2022, 162, 757-771.e4.	1.3	63
3	U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 77-90.	8.9	12
4	Contextual and individual factors associated with knowledge, awareness and attitude on liver diseases: A large-scale Asian study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 156-170.	2.0	6
5	Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study. <i>Hepatology Communications</i> , 2022, 6, 679-691.	4.3	28
6	Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis. <i>JHEP Reports</i> , 2022, 4, 100441.	4.9	12
7	Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 469-482.	7.3	41
8	Use of Proton-Pump Inhibitor Is Not Associated with Adverse Clinical Outcomes in COVID-19 Patients: A Territory-Wide Cohort Study. <i>GastroHep</i> , 2022, 2022, 1-13.	0.6	0
9	Letter: systematic review with meta-analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 616-617.	3.7	1
10	Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. <i>Hepatology</i> , 2022, 76, 1409-1422.	7.3	24
11	Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis. <i>JGH Open</i> , 2022, 6, 292-300.	1.6	10
12	Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate. <i>Journal of Medical Virology</i> , 2022, 94, 4440-4448.	5.0	5
13	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1950-1958.e7.	4.4	18
14	Monocyte-Derived Hepatocyte-Like Cell Test: A Novel Tool for in vitro Identification of Drug-Induced Liver Injury in Patients with Herbal or Dietary Supplements. <i>Digestion</i> , 2021, 102, 650-653.	2.3	4
15	Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2161-2171.e5.	4.4	119
16	Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. <i>Gut</i> , 2021, 70, 733-742.	12.1	121
17	Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase. <i>Hepatology</i> , 2021, 73, 1652-1670.	7.3	9
18	Letter to the Editor: Use of Pregenomic Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen to Predict Cure of Hepatitis B Virus Infection. <i>Hepatology</i> , 2021, 73, 870-870.	7.3	1

#	ARTICLE	IF	CITATIONS
19	Significantly Lower Case-fatality Ratio of Coronavirus Disease 2019 (COVID-19) than Severe Acute Respiratory Syndrome (SARS) in Hong Kong—A Territory-Wide Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 72, e466-e475.	5.8	26
20	Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. <i>European Journal of Internal Medicine</i> , 2021, 84, 68-73.	2.2	12
21	Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , 2021, 116, 1274-1283.	0.4	37
22	Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 961-971.	6.1	16
23	Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00300.	2.5	9
24	Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00324.	2.5	20
25	Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-Wide Cohort Study. <i>Hepatology Communications</i> , 2021, 5, 1212-1223.	4.3	9
26	A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery. <i>Scientific Reports</i> , 2021, 11, 5416.	3.3	12
27	SARS-CoV-2 Viral Persistence Based on Cycle Threshold Value and Liver Injury in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab205.	0.9	10
28	Hepatitis B Core-Related Antigen: From Virology to Clinical Application. <i>Seminars in Liver Disease</i> , 2021, 41, 182-190.	3.6	5
29	Debate settled for elevated alanine aminotransferase in hepatitis B?. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 750-751.	9.1	0
30	Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. <i>Hepatology</i> , 2021, 74, 1750-1765.	7.3	41
31	Questionnaire survey on knowledge, attitudes, and behaviour towards viral hepatitis among the Hong Kong public. , 2021, , .		4
32	Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 499-509.	8.9	14
33	Sodium-glucose co-transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B. <i>GastroHep</i> , 2021, 3, 261-269.	0.6	1
34	Secular trend of treatment uptake in patients with chronic hepatitis B: A territory-wide study of 135 395 patients from 2000 to 2017. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3487-3499.	2.8	8
35	Clinical Study of Single-stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2021, 74, 1795-1808.	7.3	24
36	Single Cell and Plasma RNA Sequencing for RNA Liquid Biopsy for Hepatocellular Carcinoma. <i>Clinical Chemistry</i> , 2021, 67, 1492-1502.	3.2	9

#	ARTICLE	IF	CITATIONS
37	Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis and renal impairment. <i>Health Science Reports</i> , 2021, 4, e352.	1.5	1
38	IDDF2021-ABS-0080...96-week efficacy and safety of tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) switch vs. continued TDF treatment among virologically-suppressed hepatitis B patients of asian ethnicity. , 2021, , .		0
39	IDDF2021-ABS-0122...No association between proton-pump inhibitor use and adverse clinical outcomes of COVID-19: a territory-wide cohort study of 8,675 patients. , 2021, , .		0
40	A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. <i>American Journal of Gastroenterology</i> , 2021, 116, 984-993.	0.4	25
41	Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 321-331.	3.7	23
42	An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017. <i>Hepatology</i> , 2020, 71, 444-455.	7.3	52
43	Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. <i>Gastroenterology</i> , 2020, 158, 215-225.e6.	1.3	156
44	Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy. <i>Gut</i> , 2020, 69, 1116-1126.	12.1	27
45	Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. <i>Journal of Hepatology</i> , 2020, 72, 57-66.	3.7	54
46	Development and validation of a model for hepatitis B e antigen seroconversion in entecavir-treated patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , 2020, 92, 1206-1213.	5.0	5
47	RNA Interference Therapy With ARC520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. <i>Hepatology</i> , 2020, 72, 19-31.	7.3	84
48	Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B. <i>Hepatology Communications</i> , 2020, 4, 8-20.	4.3	43
49	Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2843-2845.e2.	4.4	21
50	The safety of stopping nucleos(t)ide analogue treatment in patients with HBsAg-negative chronic hepatitis B. <i>Liver International</i> , 2020, 40, 549-557.	3.9	11
51	Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 847-854.	3.7	49
52	Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 581-589.	3.9	75
53	Complex genetic encoding of the hepatitis B virus on-drug persistence. <i>Scientific Reports</i> , 2020, 10, 15574.	3.3	3
54	Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors – A territory-wide cohort study. <i>Cancer Medicine</i> , 2020, 9, 7052-7061.	2.8	14

#	ARTICLE	IF	CITATIONS
55	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 776-787.	8.1	82
56	Detection and characterization of jagged ends of double-stranded DNA in plasma. <i>Genome Research</i> , 2020, 30, 1144-1153.	5.5	61
57	Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. <i>JHEP Reports</i> , 2020, 2, 100152.	4.9	18
58	Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2210-2219.	2.8	19
59	HBV variants are common in the "immune-tolerant" phase of chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1061-1070.	2.0	8
60	Reply to: "Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page". <i>Journal of Hepatology</i> , 2020, 73, 729-730.	3.7	0
61	Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong. <i>Hepatology Research</i> , 2020, 50, 1024-1031.	3.4	38
62	Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 867-875.	0.4	40
63	Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. <i>Journal of Gastroenterology</i> , 2020, 55, 899-908.	5.1	18
64	Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation. <i>Cancer Discovery</i> , 2020, 10, 664-673.	9.4	152
65	Modelling NAFLD disease burden in four Asian regions "2019-2030. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 801-811.	3.7	92
66	Editorial: increasing burden of nonalcoholic fatty liver disease "a call to action. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1430-1432.	3.7	0
67	Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1610-1618.	2.8	4
68	Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 406-417.	8.1	64
69	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 441-453.	8.1	85
70	Closing the Stable Door After the Horse Has Bolted: Should We Be Treating People With Immune-Tolerant Chronic Hepatitis B to Prevent Hepatocellular Carcinoma?. <i>Gastroenterology</i> , 2020, 158, 2028-2032.	1.3	8
71	Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study. <i>Hepatology</i> , 2020, 72, 1230-1241.	7.3	59
72	Unresolved issues of immune tolerance in chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2020, 55, 383-389.	5.1	16

#	ARTICLE	IF	CITATIONS
73	High incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: a territory-wide cohort study. <i>BMC Gastroenterology</i> , 2020, 20, 128.	2.0	6
74	Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 904-914.	2.0	17
75	Use of hepatitis B virus core-related antigen to evaluate natural history of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2202-2209.	2.8	8
76	Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1399-1406.	3.7	25
77	IDDF2020-ABS-0060...Impact of prior tenofovir disoproxil fumarate (TDF) treatment duration on tenofovir alafenamide (TAF) safety profile in virally suppressed chronic HBV patients switched from TDF to TAF. , 2020, , .		0
78	IDDF2020-ABS-0061...Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB). , 2020, , .		0
79	Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 241-248.	2.8	28
80	Gastrointestinal disease burden and mortality: A public hospital-based study from 2005 to 2014. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 124-131.	2.8	27
81	Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. <i>Scientific Reports</i> , 2019, 9, 10529.	3.3	12
82	Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1037-1048.	3.7	54
83	Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. <i>Gut</i> , 2019, 68, 2057-2064.	12.1	113
84	Low Risk of Variceal Bleeding in Patients With Cirrhosis After Variceal Screening Stratified by Liver/Spleen Stiffness. <i>Hepatology</i> , 2019, 70, 971-981.	7.3	33
85	Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1641-1647.	2.8	13
86	Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1509-1517.	3.7	14
87	Towards finite oral antiviral treatment for chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 260-262.	8.1	2
88	Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data. <i>Antiviral Therapy</i> , 2019, 24, 133-140.	1.0	9
89	Antiviral Therapy for Hepatitis B Prevents Liver Injury in Patients With Tuberculosis and Hepatitis B Coinfection. <i>Clinical Infectious Diseases</i> , 2019, 70, 660-666.	5.8	16
90	Reply to: "NAFLD and beneficial effects of lifestyle intervention: Defining the meat of the matter". <i>Journal of Hepatology</i> , 2019, 70, 1304.	3.7	0

#	ARTICLE	IF	CITATIONS
91	Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. <i>Gastroenterology</i> , 2019, 156, 1392-1403.e7.	1.3	115
92	Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 538-544.	8.1	49
93	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1969-1979.	5.8	21
94	Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. <i>Genome Research</i> , 2019, 29, 418-427.	5.5	159
95	IDDF2019-ABS-0199...The risk of metabolic acidosis in diabetic patients with different severity of chronic hepatitis B-related cirrhosis and renal impairment. , 2019, , .		0
96	IDDF2019-ABS-0168...Bone and renal safety are improved in chronic hbv patients 1 year after switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF). , 2019, , .		0
97	IDDF2019-ABS-0169...A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results. , 2019, , .		0
98	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, 916-928.	0.4	57
99	The changing epidemiology of liver diseases in the Asia-Pacific region. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 57-73.	17.8	221
100	Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B. <i>Liver International</i> , 2019, 39, 271-279.	3.9	23
101	Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 126-135.	2.0	17
102	Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 501-506.	2.8	6
103	Clinical outcomes and management of patients with chronic hepatitis B and liver stiffness measurement in the grey zone. <i>Liver International</i> , 2019, 39, 494-502.	3.9	3
104	HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. <i>Journal of Hepatology</i> , 2019, 70, 361-370.	3.7	173
105	Growth arrest-specific gene 2 suppresses hepatocarcinogenesis by intervention of cell cycle and p53-dependent apoptosis. <i>World Journal of Gastroenterology</i> , 2019, 25, 4715-4726.	3.3	13
106	96-weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. <i>Journal of Hepatology</i> , 2018, 68, 672-681.	3.7	291
107	Review article: long-term safety of oral antiviral treatment for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 730-737.	3.7	60
108	Increased expression of GATA zinc finger domain containing 1 through gene amplification promotes liver cancer by directly inducing phosphatase of regenerating liver 3. <i>Hepatology</i> , 2018, 67, 2302-2319.	7.3	16



#	ARTICLE	IF	CITATIONS
109	Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 765-773.e2.	4.4	48
110	Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016. <i>Clinical Infectious Diseases</i> , 2018, 67, 1278-1284.	5.8	39
111	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	8.1	1,241
112	Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1306-1316.	3.7	8
113	Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 484-491.	2.8	27
114	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017 Part 1: Definition, risk factors and assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 70-85.	2.8	358
115	The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017 Part 2: Management and special groups. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 86-98.	2.8	117
116	Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. <i>Journal of Viral Hepatitis</i> , 2018, 25, 228-235.	2.0	12
117	Reply to: Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , 2018, 68, 208-209.	3.7	0
118	Impact of diabetes mellitus and hepatitis B virus coinfection on patients with chronic hepatitis C: A territorywide cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 934-941.	2.8	10
119	Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. <i>Journal of Hepatology</i> , 2018, 68, 63-72.	3.7	77
120	Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. <i>Journal of Hepatology</i> , 2018, 68, 147-156.	3.7	72
121	A new screening strategy for varices by liver and spleen stiffness measurement (<scp>LSSM</scp>) in cirrhotic patients: A randomized trial. <i>Liver International</i> , 2018, 38, 636-644.	3.9	34
122	Defective lysosomal clearance of autophagosomes and its clinical implications in nonalcoholic steatohepatitis. <i>FASEB Journal</i> , 2018, 32, 37-51.	0.5	60
123	The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. <i>Liver International</i> , 2018, 38, 1179-1187.	3.9	17
124	Four-year Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 347-352.	2.2	22
125	IDDF2018-ABS-0058...Early normalisation of alanine aminotransferase (alt) after nucleos(t)ide analogue treatment reduces the risk of hepatocellular carcinoma (hcc) in patients with chronic hepatitis b a territory-wide study of 21,182 subjects. , 2018, , .		0
126	IDDF2018-ABS-0106...Tenofovir alafenamide (taf) compared with tenofovir disoproxil fumarate (tdf) in patients with chronic hbv: week 96 efficacy and safety results in chinese patients enrolled in 2 global phase 3 studies. , 2018, , .		0



#	ARTICLE	IF	CITATIONS
127	Editorial: a baseline tool for predicting response to peginterferon alfa-2a in HBsAg-positive patients" same score, different outcomes. Author's Reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 876-877.	3.7	0
128	Improvements in the management of chronic hepatitis B virus infection. Expert Review of Gastroenterology and Hepatology, 2018, 12, 1153-1166.	3.0	8
129	On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis. American Journal of Gastroenterology, 2018, 113, 1629-1638.	0.4	24
130	Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10925-E10933.	7.1	140
131	Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. Journal of Hepatology, 2018, 69, 793-802.	3.7	79
132	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. PLoS ONE, 2018, 13, e0199198.	2.5	6
133	IDDF2018-ABS-0107a...Efficacy and safety of TENOFOVIR ALAFENAMIDE (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of TENOFOVIR DISOPROXIL FUMARATE (TDF)., 2018, , .		1
134	A baseline tool for predicting response to peginterferon alfa-2a in HBsAg-positive patients with chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2018, 48, 547-555.	3.7	27
135	No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	41
136	Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. Journal of Viral Hepatitis, 2018, 25, 1429-1437.	2.0	16
137	Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. Liver International, 2018, 38, 1911-1919.	3.9	15
138	Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2018, 69, 1349-1356.	3.7	198
139	Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis. Digestive Diseases and Sciences, 2018, 63, 3487-3497.	2.3	45
140	Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment. Alimentary Pharmacology and Therapeutics, 2018, 48, 984-992.	3.7	59
141	Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases. Clinical Chemistry, 2018, 64, 1239-1249.	3.2	60
142	Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology, 2017, 65, 54-64.	7.3	260
143	The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. Hepatology, 2017, 65, 1840-1850.	7.3	74
144	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology and Hepatology, 2017, 2, 161-176.	8.1	1,619

#	ARTICLE	IF	CITATIONS
145	Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1453-1460.e1.	4.4	42
146	Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk – a cohort study of 44 494 subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1213-1224.	3.7	23
147	Tenofovir Alafenamide: A Review in Chronic Hepatitis B. <i>Drugs</i> , 2017, 77, 1017-1028.	10.9	32
148	Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 175-182.	3.7	58
149	Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1071-1078.	2.8	6
150	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. <i>Journal of Hepatology</i> , 2017, 67, 577-584.	3.7	110
151	Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (<sc>NAFLD</sc>) in the general population. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 447-456.	3.7	132
152	International incidence and mortality trends of liver cancer: a global profile. <i>Scientific Reports</i> , 2017, 7, 45846.	3.3	199
153	Reply to: “Serum HBsAg kinetics in clinical prediction”. <i>Journal of Hepatology</i> , 2017, 67, 193-194.	3.7	0
154	A Phase 3 Study of Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-negative, Chronic Hepatitis B (CHB): Week 48 Efficacy and Safety Results. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, e44.	4.4	0
155	Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1363-1369.	2.8	44
156	Prognostic Value of Controlled Attenuation Parameter by Transient Elastography. <i>American Journal of Gastroenterology</i> , 2017, 112, 1812-1823.	0.4	67
157	Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1001-1010.	3.7	48
158	RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	343
159	Hepatitis B virus infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 237.	2.4	0
160	Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with <sc>NAFLD</sc>. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 617-627.	3.7	134
161	Strategies to manage hepatitis C virus infection disease burden – Volume 4. <i>Journal of Viral Hepatitis</i> , 2017, 24, 44-63.	2.0	17
162	The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4. <i>Journal of Viral Hepatitis</i> , 2017, 24, 25-43.	2.0	26

#	ARTICLE	IF	CITATIONS
163	Historical epidemiology of hepatitis C virus in select countries" volume 4. Journal of Viral Hepatitis, 2017, 24, 8-24.	2.0	30
164	Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Journal of Hepatology, 2017, 67, 902-908.	3.7	112
165	Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 667-676.	2.8	152
166	The role of quantitative hepatitis B surface antigen revisited. Journal of Hepatology, 2017, 66, 398-411.	3.7	267
167	Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1230-1233.	2.8	16
168	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. Hepatology, 2017, 65, 1145-1155.	7.3	177
169	Liver stiffness measurement predicts high-grade post-hepatectomy liver failure: A prospective cohort study. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 506-514.	2.8	39
170	Measuring spleen stiffness to predict varices in chronic hepatitis B cirrhotic patients with or without receiving non-selective beta-blockers. Journal of Digestive Diseases, 2016, 17, 538-546.	1.5	31
171	Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 848-855.	2.8	151
172	Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. Hepatology, 2016, 63, 754-763.	7.3	101
173	Reply. Hepatology, 2016, 64, 1820-1821.	7.3	0
174	Reply. Hepatology, 2016, 64, 685-686.	7.3	1
175	Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir. Medicine (United States), 2016, 95, e2702.	1.0	34
176	Virus and Host Testing to Manage Chronic Hepatitis B. Clinical Infectious Diseases, 2016, 62, S298-S305.	5.8	12
177	Reply. Gastroenterology, 2016, 150, 1255.	1.3	1
178	Renal Function in Nucleos(t)ide Analog-Treated Patients With Chronic Hepatitis B: A Systematic Literature Review and Network Meta-Analysis. Advances in Therapy, 2016, 33, 862-875.	2.9	18
179	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. The Lancet Gastroenterology and Hepatology, 2016, 1, 185-195.	8.1	336
180	Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B. Hepatology, 2016, 64, 1507-1517.	7.3	23

#	ARTICLE	IF	CITATIONS
181	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 196-206.	8.1	377
182	Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 957-966.	3.7	35
183	Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 56-67.	8.1	152
184	Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 145-153.	3.7	30
185	Letter: factors determining liver fibrosis - more to come. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 171-172.	3.7	0
186	Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. <i>Histopathology</i> , 2016, 69, 971-984.	2.9	21
187	Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 802-813.	3.7	39
188	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , 2016, 64, 34-46.	7.3	83
189	Review article: long-term safety of nucleoside and nucleotide analogues in <sc>HBV</sc>-monoinfected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 16-34.	3.7	92
190	Liver fibrosis and fatty liver in Asian HIV-infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 411-421.	3.7	51
191	Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B. <i>Gut</i> , 2016, 65, 887-888.	12.1	39
192	Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 461-468.e2.	4.4	24
193	Infection and Cancer: The Case of Hepatitis B. <i>Journal of Clinical Oncology</i> , 2016, 34, 83-90.	1.6	131
194	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016, 64, 390-398.	3.7	64
195	Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 96-101.	3.7	26
196	Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1481-1489.e5.	4.4	51
197	Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). <i>Journal of Hepatology</i> , 2016, 64, 1011-1019.	3.7	84
198	Treatment of hepatitis C virus infection in patients with CKD. <i>Nature Reviews Nephrology</i> , 2016, 12, 5-6.	9.6	4

#	ARTICLE	IF	CITATIONS
199	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. <i>Hepatology International</i> , 2016, 10, 1-98.	4.2	1,908
200	Combination of Tenofovir Disoproxil Fumarate and Peginterferon $\alpha$ -2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2016, 150, 134-144.e10.	1.3	284
201	Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. <i>Gut</i> , 2016, 65, 1359-1368.	12.1	386
202	Bacterial endotoxin and non-alcoholic fatty liver disease in the general population: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 731-740.	3.7	57
203	Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. <i>Hepatology</i> , 2015, 62, 684-693.	7.3	77
204	Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index for Hepatocellular Carcinoma. <i>Disease Markers</i> , 2015, 2015, 1-10.	1.3	83
205	A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients. <i>Journal of Hepatology</i> , 2015, 62, 1100-1111.	3.7	63
206	Letter: association between moderate alcohol consumption and non-alcoholic fatty liver disease - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1331-1332.	3.7	0
207	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2599-2607.	27.0	945
208	Adverse Effects of Vitamin D Deficiency on Outcomes of Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 783-790.e1.	4.4	52
209	Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy. <i>Journal of Hepatology</i> , 2015, 62, 956-967.	3.7	398
210	Impact of <i>IL28B</i> and <i>PNPLA3</i> polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1040-1048.	2.8	7
211	Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1317-25.	7.1	543
212	<i>PNPLA3</i> gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 139-146.	2.8	125
213	Probability-Based Interpretation of Liver Stiffness Measurement in Untreated Chronic Hepatitis B Patients. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1448-1456.	2.3	18
214	Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. <i>Gut</i> , 2015, 64, 667-672.	12.1	185
215	Reimbursement policies in the Asia-Pacific for chronic hepatitis B. <i>Hepatology International</i> , 2015, 9, 43-51.	4.2	20
216	Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>American Journal of Gastroenterology</i> , 2015, 110, 1306-1314.	0.4	240

#	ARTICLE	IF	CITATIONS
217	Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. <i>Antiviral Research</i> , 2015, 121, 97-108.	4.1	116
218	Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. <i>Journal of Hepatology</i> , 2015, 63, 1086-1092.	3.7	49
219	Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. <i>Journal of Hepatology</i> , 2015, 63, 1190-1197.	3.7	83
220	Truncated HB $\alpha$ -dependent silencing of GAS2 promotes hepatocarcinogenesis through deregulation of cell cycle, senescence and p53-mediated apoptosis. <i>Journal of Pathology</i> , 2015, 237, 38-49.	4.5	33
221	Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection. <i>Annals of Surgical Oncology</i> , 2015, 22, 4138-4148.	1.5	206
222	New simple prognostic score for primary biliary cirrhosis: Albumin $\alpha$ bilirubin score. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1391-1396.	2.8	95
223	Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1190-1199.	3.7	7
224	Two are better than one: noninvasive assessment of liver fibrosis in nonalcoholic fatty liver disease. <i>Hepatology International</i> , 2015, 9, 481-483.	4.2	2
225	Histone Deacetylase HDAC8 Promotes Insulin Resistance and $\beta$ -Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma. <i>Cancer Research</i> , 2015, 75, 4803-4816.	0.9	105
226	Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 199-208.	3.7	51
227	Letter: pre- and post-operative anti-viral therapy is important for patients with hepatitis B virus-related hepatocellular carcinoma - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 790-790.	3.7	0
228	Incidence of non-alcoholic fatty liver disease in Hong Kong: A population study with paired proton-magnetic resonance spectroscopy. <i>Journal of Hepatology</i> , 2015, 62, 182-189.	3.7	147
229	Cost Effectiveness of Response-Guided Therapy With Peginterferon in the Treatment of Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 377-385.e5.	4.4	11
230	The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil. <i>Journal of Viral Hepatitis</i> , 2015, 22, 328-334.	2.0	23
231	Noninvasive assessments of liver fibrosis with transient elastography and Hui index predict survival in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 582-590.	2.8	12
232	Higher Estimated Net Endogenous Acid Production May Be Associated with Increased Prevalence of Nonalcoholic Fatty Liver Disease in Chinese Adults in Hong Kong. <i>PLoS ONE</i> , 2015, 10, e0122406.	2.5	28
233	Diet-Quality Scores and Prevalence of Nonalcoholic Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy. <i>PLoS ONE</i> , 2015, 10, e0139310.	2.5	77
234	Effect of pregnancy on the activity and infectivity of hepatitis B virus in women with chronic hepatitis B infection. <i>Hong Kong Medical Journal</i> , 2015, 21 Suppl 7, S4-7.	0.1	2



#	ARTICLE	IF	CITATIONS
235	Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>Infectious Diseases and Therapy</i> , 2014, 3, 191-202.	4.0	7
236	A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2014, 59, 1714-1723.	5.8	79
237	Commentary: how long does one need to fast before a Fibroscan examination?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 540-541.	3.7	1
238	Metabolic syndrome delays HBsAg seroclearance in Chinese patients with hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 716-726.	3.7	20
239	Noninvasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 197-208.	3.7	61
240	One-stop clinic for ketamine-associated uropathy: report on service delivery model, patients' characteristics and noninvasive investigations at baseline by a cross-sectional study in a prospective cohort of 318 teenagers and young adults. <i>BJU International</i> , 2014, 114, 754-760.	2.5	45
241	Editorial: metabolic syndrome delays HBsAg seroclearance in Chinese patients with hepatitis B – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 983-983.	3.7	1
242	Reply. <i>Hepatology</i> , 2014, 60, 1797-1798.	7.3	1
243	Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1485-1493.	2.8	4
244	Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B – a prospective cohort study with paired transient elastography examinations. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 883-893.	3.7	113
245	Targeted hepatitis C screening among ex-injection drug users in the community. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 116-120.	2.8	28
246	Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese. <i>Journal of Hepatology</i> , 2014, 61, 708-709.	3.7	69
247	Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2014, 60, 339-345.	3.7	227
248	Viral-Human Chimeric Transcript Predisposes Risk to Liver Cancer Development and Progression. <i>Cancer Cell</i> , 2014, 25, 335-349.	16.8	254
249	Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis. <i>Gut</i> , 2014, 63, 1793-1804.	12.1	53
250	PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 532-539.	3.7	95
251	Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2014, 21, 825-834.	2.0	32
252	Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication. <i>Histopathology</i> , 2014, 65, 174-186.	2.9	20



#	ARTICLE	IF	CITATIONS
253	On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. <i>Hepatology</i> , 2014, 59, 986-995.	7.3	114
254	Fatty Pancreas, Insulin Resistance, and Î²-Cell Function: A Population Study Using Fat-Water Magnetic Resonance Imaging. <i>American Journal of Gastroenterology</i> , 2014, 109, 589-597.	0.4	194
255	Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA. <i>Gastroenterology</i> , 2014, 146, 1240-1248.	1.3	151
256	Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin-18 fragments. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 254-269.	3.7	320
257	Liver Injury Is Common Among Chronic Abusers of Ketamine. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1759-1762.e1.	4.4	51
258	Non-alcoholic fatty liver disease: Spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study. <i>Journal of Hepatology</i> , 2014, 60, 809-815.	3.7	34
259	Hepatitis B virus infection. <i>Lancet, The</i> , 2014, 384, 2053-2063.	13.7	1,233
260	Abstract 5134: Histone deacetylase 8 is a novel chromatin modulator in NAFLD-associated hepatocarcinogenesis. , 2014, , .		0
261	Functional significance of hepatitis B virus subgenotype Cs genomic markers. <i>Hong Kong Medical Journal</i> , 2014, 20 Suppl 6, 28-30.	0.1	0
262	Non-invasive algorithm for detecting advanced liver fibrosis in chronic hepatitis B patients. <i>Hong Kong Medical Journal</i> , 2014, 20 Suppl 6, 31.	0.1	0
263	Are we ready to use the hepatitis B surface antigen level to guide peginterferon treatment in HBeAg-negative chronic hepatitis B?. <i>Hepatology International</i> , 2013, 7, 13-15.	4.2	1
264	Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. <i>Seminars in Cancer Biology</i> , 2013, 23, 471-482.	9.6	88
265	Association Between Anthropometric Parameters and Measurements of Liver Stiffness by Transient Elastography. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 295-302.e3.	4.4	64
266	Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis <sc>B</sc>: A prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1842-1848.	2.8	35
267	Hepatitis <sc>B</sc> virus reactivation associated with anti-neoplastic therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 31-37.	2.8	57
268	Treatment of non-alcoholic steatohepatitis with <i>P</i>hyllanthus urinaria</i>: A randomized trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 57-62.	2.8	23
269	Peginterferon therapy for chronic hepatitis B: one size fits all?. <i>Gut</i> , 2013, 62, 185-187.	12.1	7
270	Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis. <i>Hepatology</i> , 2013, 58, 1537-1547.	7.3	408

#	ARTICLE	IF	CITATIONS
271	Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment. <i>Gastroenterology</i> , 2013, 144, 933-944.	1.3	155
272	Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial. <i>Journal of Hepatology</i> , 2013, 59, 536-542.	3.7	254
273	Quantitative Elastography of Liver Fibrosis and Spleen Stiffness in Chronic Hepatitis B Carriers: Comparison of Shear-Wave Elastography and Transient Elastography with Liver Biopsy Correlation. <i>Radiology</i> , 2013, 269, 910-918.	7.3	267
274	Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 18761-18768.	7.1	363
275	Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: A prospective cohort study with paired transient elastography examination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1762-1769.	2.8	22
276	Chronic Hepatitis B: A Treatment Update. <i>Seminars in Liver Disease</i> , 2013, 33, 122-129.	3.6	14
277	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2332-8.	3.0	17
278	Chronic Hepatitis B: A Treatment Update. <i>Seminars in Liver Disease</i> , 2013, 33, 298-298.	3.6	0
279	Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2013, 20, e37-46.	2.0	72
280	Meta-analysis: the association of hepatitis B virus genotypes and hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 517-526.	3.7	89
281	Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. <i>Hepatology</i> , 2013, 58, 872-880.	7.3	201
282	Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis e antigen negative chronic hepatitis B patients receiving nucleos(t)ide analogues. <i>Antiviral Therapy</i> , 2013, 18, 979-986.	1.0	12
283	Liver Stiffness Measurement by Transient Elastography as a Predictor on Posthepatectomy Outcomes. <i>Annals of Surgery</i> , 2013, 257, 922-928.	4.2	96
284	Efficacy of Entecavir Switch Therapy in Chronic Hepatitis B Patients with Incomplete Virological Response to Telbivudine. <i>Antiviral Therapy</i> , 2013, 18, 671-680.	1.0	8
285	52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B. <i>PLoS ONE</i> , 2013, 8, e54279.	2.5	34
286	Molecular Characterization of the Fecal Microbiota in Patients with Nonalcoholic Steatohepatitis – A Longitudinal Study. <i>PLoS ONE</i> , 2013, 8, e62885.	2.5	266
287	Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. <i>Annals of Hepatology</i> , 2013, 12, 256-262.	1.5	252
288	Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. <i>Gut</i> , 2012, 61, 409-415.	12.1	423

#	ARTICLE	IF	CITATIONS
289	Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2012, 107, 1862-1871.	0.4	292
290	PWE-293â€¦Low glycaemic index dietary intervention for patients with non-alcoholic fatty liver disease in the general populationâ€”a randomised controlled trial. <i>Gut</i> , 2012, 61, A417.1-A417.	12.1	1
291	Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatmentâ€”naïve patients with HBVâ€”related decompensated cirrhosis. <i>Journal of Viral Hepatitis</i> , 2012, 19, 732-743.	2.0	86
292	Hepatitis B virus infection and fatty liver in the general population. <i>Journal of Hepatology</i> , 2012, 56, 533-540.	3.7	196
293	Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: Comparison between M and XL probe of FibroScanÂ®. <i>Journal of Hepatology</i> , 2012, 56, 833-839.	3.7	218
294	Assessment of nonâ€”alcoholic fatty liver disease using serum total cell death and apoptosis markers. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 1057-1066.	3.7	61
295	Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2012, 142, 513-520.e1.	1.3	171
296	Identifying Hepatitis B Carriers at Low Risk for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2012, 142, 1057-1060.	1.3	22
297	Improving transient elastography performance for detecting hepatitis B cirrhosis. <i>Digestive and Liver Disease</i> , 2012, 44, 61-66.	0.9	26
298	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. <i>Hepatology International</i> , 2012, 6, 531-561.	4.2	874
299	Use of antiviral therapy in surveillance: impact on outcome of hepatitis Bâ€”related hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 271-278.	3.9	16
300	606: Maternal HBeAg status and hepatitis B viral activity in HBsAg positive mothers. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 206, S273.	1.3	0
301	Undetectable <scp>HBV DNA</scp> at month 12 of entecavir treatment predicts maintained viral suppression and <scp>HB</scp>e<scp>A</scp>gâ€”seroconversion in chronic hepatitis <scp>B</scp> patients at 3Â”years. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1326-1335.	3.7	48
302	Responseâ€”guided therapy by hepatitis B surface antigen level for peginterferon therapy: What is next?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 420-421.	2.8	3
303	Antiviral Drug Resistance Testing in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2012, 57, 221-231.	2.3	7
304	Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. <i>Journal of Epidemiology and Community Health</i> , 2011, 65, 556-558.	3.7	40
305	High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. <i>Gut</i> , 2011, 60, 829-836.	12.1	219
306	Data Mining on DNA Sequences of Hepatitis B Virus. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2011, 8, 428-440.	3.0	44

#	ARTICLE	IF	CITATIONS
307	Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. <i>Journal of Hepatology</i> , 2011, 54, 236-242.	3.7	122
308	Is transient elastography inaccurate in chronic hepatitis B and non-alcoholic fatty liver disease?. <i>Journal of Hepatology</i> , 2011, 55, 497.	3.7	4
309	Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report. <i>Journal of Hepatology</i> , 2011, 55, 1121-1131.	3.7	280
310	Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. <i>Lancet Oncology</i> , The, 2011, 12, 568-574.	10.7	541
311	The G1613A Mutation in the HBV Genome Affects HBeAg Expression and Viral Replication through Altered Core Promoter Activity. <i>PLoS ONE</i> , 2011, 6, e21856.	2.5	26
312	On-Treatment Monitoring of Liver Fibrosis with Transient Elastography in Chronic Hepatitis B Patients. <i>Antiviral Therapy</i> , 2011, 16, 165-172.	1.0	82
313	Prediction of off-Treatment Response to Lamivudine by Serum Hepatitis B Surface Antigen Quantification in Hepatitis B E Antigen-Negative Patients. <i>Antiviral Therapy</i> , 2011, 16, 1249-1257.	1.0	100
314	Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 300-305.	2.8	127
315	Significance of hepatitis B virus genotypes and mutations in the development of hepatocellular carcinoma in Asia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 8-12.	2.8	27
316	Chronic hepatitis B in Asia – new insights from the past decade. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 131-137.	2.8	68
317	Should all patients with nonalcoholic fatty liver disease undergo oral glucose tolerance test?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 419-420.	2.8	4
318	Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 1104-1112.	3.7	159
319	Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 344-352.	3.7	107
320	Do we need a histological score to diagnose non-alcoholic steatohepatitis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 494-495.	3.7	3
321	Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 424-431.	3.7	20
322	Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 972-981.	3.7	15
323	The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography. <i>Liver International</i> , 2011, 31, 1047-1053.	3.9	31
324	Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. <i>Journal of Gastroenterology</i> , 2011, 46, 391-400.	5.1	62

#	ARTICLE	IF	CITATIONS
325	Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. <i>Hepatology</i> , 2011, 54, 1591-1599.	7.3	183
326	Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. <i>Gut</i> , 2011, 60, 1721-1727.	12.1	248
327	Viral Determinants of Hepatitis B Surface Antigen Seroclearance in Hepatitis B e Antigenâ€“Negative Chronic Hepatitis B Patients. <i>Journal of Infectious Diseases</i> , 2011, 204, 408-414.	4.0	110
328	Carboxyl-Terminal Truncated HBx Regulates a Distinct MicroRNA Transcription Program in Hepatocellular Carcinoma Development. <i>PLoS ONE</i> , 2011, 6, e22888.	2.5	73
329	Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. <i>Antiviral Therapy</i> , 2010, 15, 145-155.	1.0	38
330	Treatment of Chronic Hepatitis B in Asia-Pacific Countries: Is the Asia-Pacific Consensus Statement being followed?. <i>Antiviral Therapy</i> , 2010, 15, 607-616.	1.0	10
331	Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. <i>Hepatology International</i> , 2010, 4, 386-395.	4.2	47
332	Antiviral Therapy for Acute-on-Chronic Liver Failure in Chronic Hepatitis B: Is It Too Late?. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2126-2128.	2.3	8
333	Rate and Factors Affecting Treatment Uptake of Patients with Chronic Hepatitis C in a Tertiary Referral Hospital. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3541-3547.	2.3	19
334	Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010, 51, 454-462.	7.3	1,052
335	Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. <i>Hepatology</i> , 2010, 51, 2008-2019.	7.3	96
336	Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2010, 51, 1945-1953.	7.3	100
337	A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. <i>Hepatology</i> , 2010, 52, 1232-1241.	7.3	226
338	A magnetic beadâ€“based serum proteomic fingerprinting method for parallel analytical analysis and micropreparative purification. <i>Electrophoresis</i> , 2010, 31, 1721-1730.	2.4	17
339	Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAgâ€“negative patients. <i>Journal of Medical Virology</i> , 2010, 82, 1494-1500.	5.0	54
340	Development of a nonâ€“invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1095-1103.	3.7	110
341	Letters to the Editors: Potential pitfalls on the validation of liver stiffness measurement by Fibroscan with histological staging in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 937-938.	3.7	1
342	Metaâ€“analysis: reduction in hepatic events following interferonâ€“alpha therapy of chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1059-1068.	3.7	47

#	ARTICLE	IF	CITATIONS
343	Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1323-1331.	3.7	98
344	Individualisation of antiviral therapy for chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1206-1216.	2.8	17
345	Transient elastography. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1726-1731.	2.8	82
346	Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. <i>Gut</i> , 2010, 59, 969-974.	12.1	538
347	Metabolic syndrome and chronic hepatitis B: is the evidence enough?. <i>Gut</i> , 2010, 59, 277.1-277.	12.1	0
348	Aberrant Concentrations of Liver-Derived Plasma Albumin mRNA in Liver Pathologies. <i>Clinical Chemistry</i> , 2010, 56, 82-89.	3.2	20
349	Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. <i>Journal of Clinical Oncology</i> , 2010, 28, 1660-1665.	1.6	424
350	Interaction of Adipokines and Hepatitis B Virus on Histological Liver Injury in the Chinese. <i>American Journal of Gastroenterology</i> , 2010, 105, 132-138.	0.4	62
351	Heme Oxygenase-1 Protects Against Steatohepatitis in Both Cultured Hepatocytes and Mice. <i>Gastroenterology</i> , 2010, 138, 694-704.e1.	1.3	72
352	Reactivation of hepatitis B virus infection with persistently negative HBsAg on three HBsAg assays in a lymphoma patient undergoing chemotherapy. <i>Journal of Clinical Virology</i> , 2010, 47, 193-195.	3.1	15
353	Multiplex Detection of 60 Hepatitis B Virus Variants by MALDI-TOF Mass Spectrometry. <i>Clinical Chemistry</i> , 2009, 55, 1503-1509.	3.2	48
354	Efficacy of Cap-Assisted Colonoscopy in Comparison With Regular Colonoscopy: A Randomized Controlled Trial. <i>American Journal of Gastroenterology</i> , 2009, 104, 41-46.	0.4	125
355	Evaluation of Impact of Serial Hepatitis B Virus DNA Levels on Development of Hepatocellular Carcinoma. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1830-1836.	3.9	22
356	Glucose-regulated Protein 78 Is an Intracellular Antiviral Factor against Hepatitis B Virus. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 2582-2594.	3.8	49
357	Treatment of chronic hepatitis B: focus on telbivudine. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 259-268.	4.4	13
358	High level virion production and surface antigen expression with 1.5 copies of hepatitis B viral genome. <i>Journal of Virological Methods</i> , 2009, 159, 135-140.	2.1	2
359	Revisiting the treatment recommendations for chronic hepatitis B. <i>Hepatology</i> , 2009, 49, 700-700.	7.3	8
360	Reply:. <i>Hepatology</i> , 2009, 50, 2049-2050.	7.3	3



#	ARTICLE	IF	CITATIONS
361	High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. <i>International Journal of Cancer</i> , 2009, 124, 2766-2770.	5.1	197
362	Lamivudine monophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: A seven-year follow-up study. <i>Journal of Medical Virology</i> , 2009, 81, 224-229.	5.0	21
363	Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 387-396.	3.7	108
364	Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2009, 16, 36-44.	2.0	363
365	Evaluation of Model for End Stage Liver Disease (MELD)-based systems as prognostic index for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 63-69.	2.8	23
366	Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1002-1007.	2.8	104
367	Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 955-961.	2.8	65
368	Interferon-induced thyroid dysfunction not always transient. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 938-940.	2.8	5
369	Severe acute exacerbation of chronic hepatitis B: A unique presentation of a common disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1179-1186.	2.8	65
370	The anti-inflammatory effect of celecoxib does not prevent liver fibrosis in bile duct-ligated rats. <i>Liver International</i> , 2009, 29, 25-36.	3.9	23
371	Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1113-1120.	4.4	46
372	Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong. <i>Journal of Hepatology</i> , 2009, 51, 1088-1090.	3.7	11
373	High Incidence of Mortality and Recurrent Bleeding in Patients With Helicobacter pylori-Negative Idiopathic Bleeding Ulcers. <i>Gastroenterology</i> , 2009, 137, 525-531.	1.3	128
374	Predictors of Treatment Response in Chronic Hepatitis B. <i>Drugs</i> , 2009, 69, 2167-2177.	10.9	40
375	Clinical Factors Associated With Liver Stiffness in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 227-233.	4.4	70
376	Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab. <i>Journal of Clinical Oncology</i> , 2009, 27, 605-611.	1.6	576
377	Hepatitis B Virus Genotype C Is Associated With More Severe Liver Fibrosis Than Genotype B. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1361-1366.	4.4	75
378	Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. <i>Gut</i> , 2009, 58, 111-117.	12.1	198



#	ARTICLE	IF	CITATIONS
379	Phyllanthus urinaria ameliorates the severity of nutritional steatohepatitis both in vitro and in vivo. <i>Hepatology</i> , 2008, 47, 473-483.	7.3	36
380	Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. <i>Liver International</i> , 2008, 28, 79-87.	3.9	105
381	Role of hepatitis B virus genotypes and quantitative HBV DNA in metastasis and recurrence of hepatocellular carcinoma. <i>Journal of Medical Virology</i> , 2008, 80, 591-597.	5.0	49
382	Health-related quality of life in Chinese patients with primary biliary cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 592-598.	2.8	14
383	Association of cytokine gene polymorphisms and liver fibrosis in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 783-789.	2.8	22
384	Genetic polymorphisms of adiponectin and tumor necrosis factor- $\alpha$ and nonalcoholic fatty liver disease in Chinese people. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 914-921.	2.8	60
385	Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 1067-1077.	3.7	338
386	A complete genomic analysis of hepatitis B virus genotypes and mutations in HBeAg-negative chronic hepatitis B in China. <i>Journal of Viral Hepatitis</i> , 2008, 15, 449-458.	2.0	14
387	Elevated Perioperative Transaminase Level Predicts Intrahepatic Recurrence in Hepatitis B-related Hepatocellular Carcinoma After Curative Hepatectomy. <i>Asian Journal of Surgery</i> , 2008, 31, 41-49.	0.4	39
388	Comparison of EUS and ERCP in the investigation with suspected biliary obstruction caused by choledocholithiasis: a randomized study. <i>Gastrointestinal Endoscopy</i> , 2008, 67, 660-668.	1.0	119
389	A Randomized Controlled Study Comparing Cap-Assisted Colonoscopy Versus Conventional Colonoscopy: The Final Result. <i>Gastrointestinal Endoscopy</i> , 2008, 67, AB88.	1.0	0
390	Early Hepatitis B Virus DNA Suppression Can Predict Virologic Response to Peginterferon and Lamivudine Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1022-1026.	4.4	24
391	Elucidation of the role of COX-2 in liver fibrogenesis using transgenic mice. <i>Biochemical and Biophysical Research Communications</i> , 2008, 372, 571-577.	2.1	29
392	COX-2 mediates hepatitis B virus X protein abrogation of p53-induced apoptosis. <i>Biochemical and Biophysical Research Communications</i> , 2008, 374, 175-180.	2.1	35
393	A1762T/G1764A mutations of hepatitis B virus, associated with the increased risk of hepatocellular carcinoma, reduce basal core promoter activities. <i>Biochemical and Biophysical Research Communications</i> , 2008, 374, 773-776.	2.1	26
394	Assessment of Fibrosis by Transient Elastography Compared With Liver Biopsy and Morphometry in Chronic Liver Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1027-1035.	4.4	143
395	Validation of the NAFLD Fibrosis Score in a Chinese Population With Low Prevalence of Advanced Fibrosis. <i>American Journal of Gastroenterology</i> , 2008, 103, ???-???	0.4	101
396	Genotype-Specific Genomic Markers Associated with Primary Hepatomas, Based on Complete Genomic Sequencing of Hepatitis B Virus. <i>Journal of Virology</i> , 2008, 82, 3604-3611.	3.4	63

#	ARTICLE	IF	CITATIONS
397	Evaluation of Alanine Transaminase and Hepatitis B Virus DNA to Predict Liver Cirrhosis in Hepatitis B e Antigen-Negative Chronic Hepatitis B Using Transient Elastography. <i>American Journal of Gastroenterology</i> , 2008, 103, 3071-3081.	0.4	83
398	Quantitative Analysis of Circulating Methylated DNA as a Biomarker for Hepatocellular Carcinoma. <i>Clinical Chemistry</i> , 2008, 54, 1528-1536.	3.2	141
399	High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated With Increased Risk of Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 177-182.	1.6	278
400	A review of telbivudine for the management of chronic hepatitis B virus infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 1351-1361.	3.3	11
401	Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kDa; PEGASYS). <i>Antiviral Therapy</i> , 2008, 13, 555-62.	1.0	4
402	Treatment of Patients with Chronic Hepatitis B who have Failed Previous Antiviral Treatment with Pegylated Interferon $\alpha$ 2a (40 kDa; PEGASYS®). <i>Antiviral Therapy</i> , 2008, 13, 555-562.	1.0	12
403	Expression of a cyclo-oxygenase-2 transgene in murine liver causes hepatitis. <i>Gut</i> , 2007, 56, 991-999.	12.1	38
404	Response to Drs. Navaneethan and Jayanthi. <i>American Journal of Gastroenterology</i> , 2007, 102, 456-456.	0.4	1
405	High-Throughput Quantitative Profiling of Serum N-Glycome by MALDI-TOF Mass Spectrometry and N-Glycomic Fingerprint of Liver Fibrosis. <i>Clinical Chemistry</i> , 2007, 53, 1254-1263.	3.2	52
406	Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis with Telbivudine or Adefovir. <i>Annals of Internal Medicine</i> , 2007, 147, 745.	3.9	175
407	Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis. <i>Biochemical and Biophysical Research Communications</i> , 2007, 356, 53-59.	2.1	14
408	RNA interference targeting HBx suppresses tumor growth and enhances cisplatin chemosensitivity in human hepatocellular carcinoma. <i>Cancer Letters</i> , 2007, 253, 43-52.	7.2	39
409	Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. <i>Lancet</i> , The, 2007, 369, 1621-1626.	13.7	297
410	Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1462-1468.	4.4	320
411	Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C. <i>Hepatology</i> , 2007, 46, 315-323.	7.3	36
412	Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in chinese patients with chronic hepatitis B. <i>Liver Transplantation</i> , 2007, 13, 1228-1235.	2.4	53
413	Can dietetic intervention for obesity ever succeed in real life?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 459-460.	2.8	4
414	How should we manage patients with non-alcoholic fatty liver disease in 2007?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 801-808.	2.8	67

#	ARTICLE	IF	CITATIONS
415	Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 891-898.	3.7	38
416	Metabolic and Adipokine Profile of Chinese Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1154-1161.	4.4	181
417	Effect of celecoxib on experimental liver fibrosis in rat. <i>Liver International</i> , 2006, 26, 125-136.	3.9	47
418	Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1703-1711.	3.7	15
419	Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1215-1222.	3.7	88
420	Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients. <i>Diabetologia</i> , 2006, 49, 1777-1784.	6.3	50
421	Antiviral effect of <i>Phyllanthus nanus</i> ethanolic extract against hepatitis B virus (HBV) by expression microarray analysis. <i>Journal of Cellular Biochemistry</i> , 2006, 97, 795-812.	2.6	32
422	Hepatocellular Carcinoma and Hepatitis B Virus. <i>Seminars in Liver Disease</i> , 2006, 26, 153-161.	3.6	198
423	Phylogenetic, Virological, and Clinical Characteristics of Genotype C Hepatitis B Virus with TCC at Codon 15 of the Precore Region. <i>Journal of Clinical Microbiology</i> , 2006, 44, 681-687.	3.9	23
424	The Molecular Diagnosis of Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2006, 43, 69-101.	6.1	12
425	Evaluation of Model for End-Stage Liver Disease for Prediction of Mortality in Decompensated Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2006, 101, 1516-1523.	0.4	59
426	Histological progression of non-alcoholic fatty liver disease in Chinese patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 407-413.	3.7	81
427	Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 519-528.	3.7	48
428	Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , 2005, 41, 1357-1364.	7.3	77
429	Molecular virology in chronic hepatitis B: genotypes. <i>British Journal of Hospital Medicine (London,)</i> Tj ETQq1 1 0.784314 rgBTg/Overlo	0.5	
430	Epidemiological and Virological Characteristics of 2 Subgroups of Hepatitis B Virus Genotype C. <i>Journal of Infectious Diseases</i> , 2005, 191, 2022-2032.	4.0	92
431	Clopidogrel versus Aspirin and Esomeprazole to Prevent Recurrent Ulcer Bleeding. <i>New England Journal of Medicine</i> , 2005, 352, 238-244.	27.0	567
432	A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon- $\alpha$ 2b and Lamivudine with Lamivudine Alone. <i>Annals of Internal Medicine</i> , 2005, 142, 240.	3.9	248

#	ARTICLE	IF	CITATIONS
433	Identification of Chronic Hepatitis B Patients without Significant Liver Fibrosis by a Simple Noninvasive Predictive Model. <i>American Journal of Gastroenterology</i> , 2005, 100, 616-623.	0.4	200
434	An Intensive Surveillance Program Detected a High Incidence of Hepatocellular Carcinoma Among Hepatitis B Virus Carriers With Abnormal Alpha-Fetoprotein Levels or Abdominal Ultrasonography Results. <i>Journal of Clinical Oncology</i> , 2005, 23, 8041-8047.	1.6	36
435	Prediction of Liver Fibrosis and Cirrhosis in Chronic Hepatitis B Infection by Serum Proteomic Fingerprinting: A Pilot Study. <i>Clinical Chemistry</i> , 2005, 51, 328-335.	3.2	125
436	Anti-proliferative and pro-apoptotic effects of herbal medicine on hepatic stellate cell. <i>Journal of Ethnopharmacology</i> , 2005, 100, 180-186.	4.1	59
437	Transmission of hepatitis B by human bite—Confirmation by detection of virus in saliva and full genome sequencing. <i>Journal of Clinical Virology</i> , 2005, 33, 254-256.	3.1	33
438	A hospital clinic-based survey on traditional Chinese medicine usage among chronic hepatitis B patients. <i>Complementary Therapies in Medicine</i> , 2005, 13, 175-182.	2.7	28
439	Intrahepatic Hepatitis B Virus Covalently Closed Circular DNA Can Be a Predictor of Sustained Response to Therapy. <i>Gastroenterology</i> , 2005, 128, 1890-1897.	1.3	207
440	Long-term Outcome of Helicobacter pylori—Negative Idiopathic Bleeding Ulcers: A Prospective Cohort Study. <i>Gastroenterology</i> , 2005, 128, 1845-1850.	1.3	105
441	A Retrospective Study on Clinical Features and Prognostic Factors of Biopsy-Proven Primary Biliary Cirrhosis in Chinese Patients. <i>American Journal of Gastroenterology</i> , 2005, 100, 2205-2211.	0.4	29
442	Clinical significance of hepatic derangement in severe acute respiratory syndrome. <i>World Journal of Gastroenterology</i> , 2005, 11, 2148.	3.3	38
443	Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. <i>Gut</i> , 2004, 53, 1494-1498.	12.1	455
444	Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophyllaxis. <i>Clinical Transplantation</i> , 2004, 18, 295-300.	1.6	33
445	Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 323-329.	3.7	25
446	Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 45-49.	3.7	50
447	Quantitative assessment of fibrosis in liver biopsies from patients with chronic hepatitis B. <i>Liver International</i> , 2004, 24, 611-618.	3.9	48
448	Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. <i>Modern Pathology</i> , 2004, 17, 1169-1179.	5.5	89
449	Effect of prostaglandin E2 and prostaglandin I2 on PDGF-induced proliferation of LI90, a human hepatic stellate cell line. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2004, 71, 329-333.	2.2	15
450	Impact of severe acute respiratory syndrome on liver transplantation service. <i>Transplantation Proceedings</i> , 2004, 36, 2302-2303.	0.6	21

#	ARTICLE	IF	CITATIONS
451	Absence of impact of donor hepatic steatosis and posttransplantation lamivudine resistance in a patient with chronic hepatitis B. <i>Transplantation Proceedings</i> , 2004, 36, 2309-2310.	0.6	0
452	Complications of liver donation for living related liver transplantation. <i>Transplantation Proceedings</i> , 2004, 36, 2224-2225.	0.6	3
453	Multimodality tumor control and living donor transplantation for unresectable hepatocellular carcinoma. <i>Transplantation Proceedings</i> , 2004, 36, 2287-2288.	0.6	5
454	Retrospective analysis of liver function derangement in severe acute respiratory syndrome. <i>American Journal of Medicine</i> , 2004, 116, 566-567.	1.5	21
455	A Cost Comparison of Management of Chronic Hepatitis B and Its Associated Complications in Hong Kong and Singapore. <i>Journal of Clinical Gastroenterology</i> , 2004, 38, S136-S143.	2.2	29
456	Adoptive immune transfer in liver transplantation of HBV-related liver diseases. <i>Hepatology</i> , 2003, 37, 1224-1225.	7.3	2
457	Fulminant hepatic failure in a patient with inactive HBsAg carrier state, acute hepatitis E and thyrotoxicosis. <i>Hepatology Research</i> , 2003, 27, 248-251.	3.4	8
458	Double-blinded placebo-controlled study of <i>Phyllanthus urinaris</i> for the treatment of chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 339-345.	3.7	19
459	Fatal outcome of SARS in a patient with reactivation of chronic hepatitis B. <i>American Journal of Medicine</i> , 2003, 115, 334-336.	1.5	8
460	Liver transplantation for hepatocellular carcinoma in cirrhotic patients—a single-center experience. <i>Transplantation Proceedings</i> , 2003, 35, 379-380.	0.6	3
461	Immunosuppression with rapid steroid reduction among predominantly HBV liver transplantation recipients: initial experience. <i>Transplantation Proceedings</i> , 2003, 35, 419-420.	0.6	1
462	Virological and histological outcome of a patient with chronic hepatitis B transplanted with liver from hepatitis C virus—positive donor. <i>Transplantation Proceedings</i> , 2003, 35, 423-424.	0.6	0
463	High incidence of incidental hepatocellular carcinoma exists among hepatic explanted livers. <i>Transplantation Proceedings</i> , 2003, 35, 350-351.	0.6	16
464	Coronavirus in severe acute respiratory syndrome (SARS). <i>Trends in Molecular Medicine</i> , 2003, 9, 323-325.	6.7	28
465	Hepatitis B Virus Genotype C Takes a More Aggressive Disease Course Than Hepatitis B Virus Genotype B in Hepatitis B e Antigen-Positive Patients. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1277-1279.	3.9	127
466	Use of Hepatitis B Virus DNA Quantitation To Predict Hepatitis B e Antigen Reversion in Cases of Chronic Hepatitis B. <i>Journal of Clinical Microbiology</i> , 2003, 41, 4793-4795.	3.9	22
467	A cirrhotic patient with fever and abdominal pain in the presence of ascites. <i>British Journal of Hospital Medicine</i> , 2003, 64, 310-310.	0.2	1
468	Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. <i>World Journal of Gastroenterology</i> , 2003, 9, 2695.	3.3	50

#	ARTICLE	IF	CITATIONS
469	Icteric flare of chronic hepatitis B in a 95-year old patient. <i>World Journal of Gastroenterology</i> , 2003, 9, 2876.	3.3	1
470	Genotype B hepatitis B virus is associated with severe icteric flare-up of chronic hepatitis B virus infection in Hong Kong. <i>American Journal of Gastroenterology</i> , 2002, 97, 2629-2633.	0.4	27
471	Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. <i>American Journal of Gastroenterology</i> , 2002, 97, 406-412.	0.4	131
472	Survival and Prognostic Indicators in Patients with Hepatitis B Virus-Related Cirrhosis After Onset of Hepatic Decompensation. <i>Journal of Clinical Gastroenterology</i> , 2002, 34, 569-572.	2.2	92
473	Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. <i>American Journal of Gastroenterology</i> , 2002, 97, 1211-1215.	0.4	75
474	Eradication of <i>Helicobacter pylori</i> and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. <i>Lancet</i> , The, 2002, 359, 9-13.	13.7	316
475	Changing scene in hepatitis B serology interpretation. <i>British Journal of Hospital Medicine</i> , 2002, 63, 16-19.	0.2	18
476	Factors associated with viral breakthrough in lamivudine monophylaxis of hepatitis B virus recurrence after liver transplantation. <i>Journal of Medical Virology</i> , 2002, 68, 182-187.	5.0	81
477	Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. <i>Journal of Viral Hepatitis</i> , 2002, 9, 229-234.	2.0	47
478	The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. <i>Journal of Viral Hepatitis</i> , 2002, 9, 424-428.	2.0	68
479	Expression of cyclooxygenase-2 in chronic hepatitis B and the effects of anti-viral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 251-260.	3.7	29
480	Is non- <i>Helicobacter pylori</i> , non-NSAID peptic ulcer a common cause of upper GI bleeding? A prospective study of 977 patients. <i>Gastrointestinal Endoscopy</i> , 2001, 53, 438-442.	1.0	87
481	Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1737-1744.	3.7	46
482	The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1899-1905.	3.7	65
483	Hepatitis B e antigen-negative chronic hepatitis b in Hong Kong. <i>Hepatology</i> , 2000, 31, 763-768.	7.3	190
484	Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus-infected patients. <i>American Journal of Gastroenterology</i> , 2000, 95, 3547-3551.	0.4	19
485	Comparison of Three Different Sensitive Assays for Hepatitis B Virus DNA in Monitoring of Responses to Antiviral Therapy. <i>Journal of Clinical Microbiology</i> , 2000, 38, 3205-3208.	3.9	41
486	Different hepatitis b virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. <i>Hepatology</i> , 1999, 29, 976-984.	7.3	251